Cutaneous T-Cell Lymphoma after Dupilumab Use: A Real-World Pharmacovigilance Study of the FDA Adverse Event Reporting System.

ABSTRACT:

SUBMITTER: Lavin L 

PROVIDER: S-EPMC11625630 | biostudies-literature | 2025 Jan

REPOSITORIES: biostudies-literature